戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  18.1% for bacterial vaginosis, and 8.6% for vulvovaginal candidiasis.
2 o colonization and immunopathogenesis during vulvovaginal candidiasis.
3  protection in oral infection but exacerbate vulvovaginal candidiasis.
4 ed to fluid from healthy women or women with vulvovaginal candidiasis.
5  March 2001 from 429 patients with suspected vulvovaginal candidiasis.
6 reduce the rate of recurrence of symptomatic vulvovaginal candidiasis.
7 zole was effective in preventing symptomatic vulvovaginal candidiasis.
8 be effective for the management of recurrent vulvovaginal candidiasis.
9 acy to fluconazole in the treatment of acute vulvovaginal candidiasis.
10 lbicans, in mice models of oropharyngeal and vulvovaginal candidiasis.
11 conazole, are now available for treatment of vulvovaginal candidiasis.
12 trial, NDV-3A protected women from recurrent vulvovaginal candidiasis.
13 of oral ibrexafungerp in patients with acute vulvovaginal candidiasis.
14                                              Vulvovaginal candidiasis affects approximately 75% of wo
15 anslocation, nor do we implicate the gene in vulvovaginal candidiasis among mice in pseudoestrus.
16 oth clinical studies of women with recurrent vulvovaginal candidiasis and a murine model of experimen
17  24 premenopausal women with acute recurrent vulvovaginal candidiasis and from 21 healthy asymptomati
18 eatment-emergent adverse events (TEAEs) were vulvovaginal candidiasis and nausea (each 2.7%).
19  infection, Trichomonas vaginalis infection, vulvovaginal candidiasis, and bacterial vaginosis) in HI
20  diarrhea, C. difficile infection, vaginitis/vulvovaginal candidiasis, and pneumonia.
21 ted to testing for bacterial vaginosis (BV), vulvovaginal candidiasis, and trichomoniasis.
22                                              Vulvovaginal candidiasis, caused primarily by Candida al
23                                 In contrast, vulvovaginal candidiasis has a much weaker association w
24 ), gonorrhea (HR, 1.6; 95% CI, 1.1-2.2), and vulvovaginal candidiasis (HR, 1.5; 95% CI, 1.3-1.8).
25 p-based vaccine, protected against recurrent vulvovaginal candidiasis in women.
26                         The risks of GUD and vulvovaginal candidiasis increased with progressive leve
27 ch higher numbers of bacterial vaginosis and vulvovaginal candidiasis infections.
28 chlamydia, bacterial vaginosis, trichomonas, vulvovaginal candidiasis, pelvic inflammatory disease, g
29                                    Recurrent vulvovaginal candidiasis (RVVC) affects up to 8% of wome
30            Studies from women with recurrent vulvovaginal candidiasis (RVVC) and from an animal model
31 not associated with development of recurrent vulvovaginal candidiasis (RVVC) in women.
32        The estimated prevalence of recurrent vulvovaginal candidiasis (RVVC) was 2,739/100,000.
33 e and susceptibility to recurrent idiopathic vulvovaginal candidiasis (RVVC) was investigated.
34 is sensitivity 61.6%, specificity 46.0%; and vulvovaginal candidiasis sensitivity 74.6%, specificity
35 and moderate sensitivity and specificity for vulvovaginal candidiasis (sensitivity 64.4%, specificity
36 e antifungal susceptibility of yeast causing vulvovaginal candidiasis, since cultures are rarely perf
37  women with non-antibiotic-induced recurrent vulvovaginal candidiasis suffering from acute Candida va
38 ypeptides in both bacterial vaginosis and in vulvovaginal candidiasis, suggesting that the abnormalit
39                                    Unlike in vulvovaginal candidiasis, the neutrophil attractant chem
40 e randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluco
41                                 In mice with vulvovaginal candidiasis, topical dextran sulfate admini
42 pain; non-Clostridioides difficile diarrhea; vulvovaginal candidiasis/vaginitis).
43                             The diagnosis of vulvovaginal candidiasis (VVC) by the Affirm and Candida
44                                              Vulvovaginal candidiasis (VVC) caused by Candida albican
45                                              Vulvovaginal candidiasis (VVC) caused by Candida albican
46                                              Vulvovaginal candidiasis (VVC) caused by the commensal o
47 da causes an estimated half-billion cases of vulvovaginal candidiasis (VVC) every year.
48 sseminated candidiasis (HDC) and episodes of vulvovaginal candidiasis (VVC) in humans, we found evide
49                                              Vulvovaginal candidiasis (VVC) is a common cause of vulv
50                                              Vulvovaginal candidiasis (VVC) is a common mucosal infec
51                                              Vulvovaginal candidiasis (VVC) is a high-incidence disea
52                                              Vulvovaginal candidiasis (VVC) is an insidious infection
53                                              Vulvovaginal candidiasis (VVC) is an opportunistic mucos
54                                        Acute vulvovaginal candidiasis (VVC) is common among women, bu
55                         Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azo
56  Candida test using a reference standard for vulvovaginal candidiasis (VVC) of yeast culture plus exc
57                 Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) present serious reproduct
58                          Acute and recurrent vulvovaginal candidiasis (VVC) remains a significant pro
59  bacterial vaginosis (BV) and/or symptomatic vulvovaginal candidiasis (VVC), 195 (18.5%) had one or m
60 s the causative agent of acute and recurrent vulvovaginal candidiasis (VVC), a common mucosal infecti
61 rial vaginosis (BV), 25 acquired symptomatic vulvovaginal candidiasis (VVC), and 7 acquired vaginal t
62 re assessed for bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), and tested for M. homini
63 s vaginitis due to bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginali
64 mmon, diagnosis of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginali
65 ion with lactobacilli may reduce the risk of vulvovaginal candidiasis (VVC), but supporting data are
66                                              Vulvovaginal candidiasis (VVC), caused by Candida albica
67                                              Vulvovaginal candidiasis (VVC), caused by Candida specie
68                                              Vulvovaginal candidiasis (VVC), caused primarily by Cand
69 opharyngeal candidiasis (OPC), as opposed to vulvovaginal candidiasis (VVC), is a common opportunisti
70                                              Vulvovaginal candidiasis (VVC), mainly caused by Candida
71 ections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or Trichomonas vaginalis
72 ctions, notably bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), particularly in the sett
73 t common infection caused by Candida spp. is vulvovaginal candidiasis (VVC), which affects >70% of wo
74 st commonly as oropharyngeal candidiasis and vulvovaginal candidiasis (VVC).
75 = 2) with OPC in 1 patient, whereas isolated vulvovaginal candidiasis (VVC; n = 3) was not.
76  b-), the relative risk of chronic recurring vulvovaginal candidiasis was 2.41-4.39, depending on the
77                                              Vulvovaginal candidiasis was treated presumptively.
78 hoeae, T vaginalis, bacterial vaginosis, and vulvovaginal candidiasis were the gold standard, and all